True Leaf Medicine International (CSE:MJ) announced that it has secured coast-to-coast distribution for its new Trueleafpet™ Hemp Chew product line, which will be launched this fall.
As quoted in the press release:

Freedom Pet Supplies (Freedom) has agreed to service Ontario to Prince Edward Island and Anipet Animal Supplies Inc. (Anipet) will cover the western provinces. Both companies cover the entire Canadian pet specialty marketplace, servicing over 2800 stores between them.
These distribution agreements will support True Leaf’s strategic decision to enter the $60 billion pet industry with a line of hemp-focused pet products. Initially, True Leaf will market pet chews through direct, pet, natural health and veterinary channels in Canada and the US.
Freedom Pet Supplies Inc. ( was established in September 2001 by John and Kelly Ayres and focuses on selling quality products to independent pet product dealers and major pet specialty retail chains, from Ontario to Newfoundland. The company is known for its superior customer service and close-knit company culture. It has grown to over 91 employees at its Cambridge, Ontario location.

Darcy Bomford, CEO of True Leaf, commented:

Both companies sell North America’s most successful pet brands and cover 100% of the independent retailers and pet-specialty chains in Canada. I’ve known the people behind both companies for years and couldn’t be happier with our new partners to help grow our business.

Click here to read the full True Leaf Medicine International (CSE:MJ) press release.

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less